Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment

U. Ambrosetti, E. Dondè, G. Piatti, M. D. Cappellini

Research output: Contribution to journalArticle

Abstract

With the improved life expectation of β-thalassemia major patients, new clinical problems, such as hearing damage, must be evaluated. Fifty-seven patients (32 F, 25 M; age range 17-32 years) have been studied to define risk factors for development of sensorineural hearing loss. All patients with β-thalassemia major received daily chelation therapy with subcutaneous injection of desferrioxamine (30-50 mg kg -1 per day). We performed an otological visit and pure tone audiometry as well as impedance; patients were followed for 3 years. Four patients with a conductive hearing loss were excluded; 66.6% had a normal audiogram; 22.8% had a slight sensorineural deficit (≤35 dB HL) with high frequency losses; only two patients (3.5%) had a moderate deficit (between 35 and 75 dB HL). In normal subjects ABR recording gave normal values. There was no association between age, ferritin level, therapeutic index (T.I.) and hearing loss. We conclude that no significant difference exists between β-thalassemic patients and non-thalassemic subjects of the same age; desferrioxamine treatment seem to be non-ototoxic when employed at the present dosages, but the ototoxicity is probably related to individual susceptibility that is unforeseeable; in any case, the risk of ototoxicity seems to be much less than the benefits which derive from the use of this drug. (C) 2000 Academic Press.

Original languageEnglish
Pages (from-to)485-487
Number of pages3
JournalPharmacological Research
Volume42
Issue number5
DOIs
Publication statusPublished - 2000

Fingerprint

beta-Thalassemia
Deferoxamine
Therapeutics
Chelation Therapy
Conductive Hearing Loss
Pure-Tone Audiometry
Sensorineural Hearing Loss
Subcutaneous Injections
Ferritins
Electric Impedance
Hearing Loss
Hearing
Reference Values
Pharmaceutical Preparations

Keywords

  • β-thalassemia
  • Desferrioxamine
  • Ototoxicity
  • Sensorineural hearing loss

ASJC Scopus subject areas

  • Pharmacology

Cite this

Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. / Ambrosetti, U.; Dondè, E.; Piatti, G.; Cappellini, M. D.

In: Pharmacological Research, Vol. 42, No. 5, 2000, p. 485-487.

Research output: Contribution to journalArticle

@article{74db6e0338aa474b84dda1b8ebefb2ea,
title = "Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment",
abstract = "With the improved life expectation of β-thalassemia major patients, new clinical problems, such as hearing damage, must be evaluated. Fifty-seven patients (32 F, 25 M; age range 17-32 years) have been studied to define risk factors for development of sensorineural hearing loss. All patients with β-thalassemia major received daily chelation therapy with subcutaneous injection of desferrioxamine (30-50 mg kg -1 per day). We performed an otological visit and pure tone audiometry as well as impedance; patients were followed for 3 years. Four patients with a conductive hearing loss were excluded; 66.6{\%} had a normal audiogram; 22.8{\%} had a slight sensorineural deficit (≤35 dB HL) with high frequency losses; only two patients (3.5{\%}) had a moderate deficit (between 35 and 75 dB HL). In normal subjects ABR recording gave normal values. There was no association between age, ferritin level, therapeutic index (T.I.) and hearing loss. We conclude that no significant difference exists between β-thalassemic patients and non-thalassemic subjects of the same age; desferrioxamine treatment seem to be non-ototoxic when employed at the present dosages, but the ototoxicity is probably related to individual susceptibility that is unforeseeable; in any case, the risk of ototoxicity seems to be much less than the benefits which derive from the use of this drug. (C) 2000 Academic Press.",
keywords = "β-thalassemia, Desferrioxamine, Ototoxicity, Sensorineural hearing loss",
author = "U. Ambrosetti and E. Dond{\`e} and G. Piatti and Cappellini, {M. D.}",
year = "2000",
doi = "10.1006/phrs.2000.0722",
language = "English",
volume = "42",
pages = "485--487",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "5",

}

TY - JOUR

T1 - Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment

AU - Ambrosetti, U.

AU - Dondè, E.

AU - Piatti, G.

AU - Cappellini, M. D.

PY - 2000

Y1 - 2000

N2 - With the improved life expectation of β-thalassemia major patients, new clinical problems, such as hearing damage, must be evaluated. Fifty-seven patients (32 F, 25 M; age range 17-32 years) have been studied to define risk factors for development of sensorineural hearing loss. All patients with β-thalassemia major received daily chelation therapy with subcutaneous injection of desferrioxamine (30-50 mg kg -1 per day). We performed an otological visit and pure tone audiometry as well as impedance; patients were followed for 3 years. Four patients with a conductive hearing loss were excluded; 66.6% had a normal audiogram; 22.8% had a slight sensorineural deficit (≤35 dB HL) with high frequency losses; only two patients (3.5%) had a moderate deficit (between 35 and 75 dB HL). In normal subjects ABR recording gave normal values. There was no association between age, ferritin level, therapeutic index (T.I.) and hearing loss. We conclude that no significant difference exists between β-thalassemic patients and non-thalassemic subjects of the same age; desferrioxamine treatment seem to be non-ototoxic when employed at the present dosages, but the ototoxicity is probably related to individual susceptibility that is unforeseeable; in any case, the risk of ototoxicity seems to be much less than the benefits which derive from the use of this drug. (C) 2000 Academic Press.

AB - With the improved life expectation of β-thalassemia major patients, new clinical problems, such as hearing damage, must be evaluated. Fifty-seven patients (32 F, 25 M; age range 17-32 years) have been studied to define risk factors for development of sensorineural hearing loss. All patients with β-thalassemia major received daily chelation therapy with subcutaneous injection of desferrioxamine (30-50 mg kg -1 per day). We performed an otological visit and pure tone audiometry as well as impedance; patients were followed for 3 years. Four patients with a conductive hearing loss were excluded; 66.6% had a normal audiogram; 22.8% had a slight sensorineural deficit (≤35 dB HL) with high frequency losses; only two patients (3.5%) had a moderate deficit (between 35 and 75 dB HL). In normal subjects ABR recording gave normal values. There was no association between age, ferritin level, therapeutic index (T.I.) and hearing loss. We conclude that no significant difference exists between β-thalassemic patients and non-thalassemic subjects of the same age; desferrioxamine treatment seem to be non-ototoxic when employed at the present dosages, but the ototoxicity is probably related to individual susceptibility that is unforeseeable; in any case, the risk of ototoxicity seems to be much less than the benefits which derive from the use of this drug. (C) 2000 Academic Press.

KW - β-thalassemia

KW - Desferrioxamine

KW - Ototoxicity

KW - Sensorineural hearing loss

UR - http://www.scopus.com/inward/record.url?scp=0033735939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033735939&partnerID=8YFLogxK

U2 - 10.1006/phrs.2000.0722

DO - 10.1006/phrs.2000.0722

M3 - Article

C2 - 11023713

AN - SCOPUS:0033735939

VL - 42

SP - 485

EP - 487

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 5

ER -